Literature DB >> 17598974

Fas/Fas ligand gene polymorphism in patients with papillary thyroid cancer in the Turkish population.

M Erdogan1, M Karadeniz, A Berdeli, S Tamsel, Y Ertan, H Uluer, C Yilmaz, M Tuzun, T Kabalak, A G Ozgen.   

Abstract

OBJECTIVE: Fas ligand (FasL) is an apoptotic agent and a member of tumor necrosis factor (TNF) family. FasL exists in cytotoxic T lymphocyte (CTL) and natural killer (NK) cells, and it is increased in tumor cell membrane. On the contrary, CTL and NK are bound to Fas on the surfaces of cell membrane; this triggers apoptosis in cytotoxic cells and leads to their death. This system plays an important role in eliminating viral infections and cancer cells. Malfunction of this system results in the development and spread of the malignancy. This study aims at evaluating the influence of Fas and FasL gene polymorphism in papillary thyroid cancer (PTC) in the Turkish population. RESEARCH DESIGN AND METHODS: Forty-five patients with PTC and 100 healthy controls were included in this study. The diagnosis of PTC was confirmed by histopathologic examination after surgery. The evaluation of genotype for Fas 670 A/G and FasL 843 C/T gene polymorphism was performed using the PCR-restriction fragment length polymorphism (RFLP) method.
RESULTS: The evaluation of Fas/FasL genotype and gene allele frequency did not show statistically significant differences between the patient and control group (p>0.05). In addition, the univariate analysis did not reveal a statistically significant relationship between the size of the nodule and the Fas/FasL gene polymorphism in patients with PTC.
CONCLUSIONS: As in other types of malignancy, genetic factors in the pathogenesis of PTC may also show changes in different populations. Fas/FasL gene polymorphysms are possible that different mechanisms function in apoptosis balance in PTC development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17598974     DOI: 10.1007/BF03346319

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  29 in total

1.  The RET receptor: function in development and dysfunction in congenital malformation.

Authors:  S Manié; M Santoro; A Fusco; M Billaud
Journal:  Trends Genet       Date:  2001-10       Impact factor: 11.639

2.  Frequent mutations of Fas gene in thyroid lymphoma.

Authors:  T Takakuwa; Z Dong; H Takayama; F Matsuzuka; S Nagata; K Aozasa
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

Review 3.  Molecular classification and biomarker discovery in papillary thyroid carcinoma.

Authors:  Orla Sheils
Journal:  Expert Rev Mol Diagn       Date:  2005-11       Impact factor: 5.225

4.  Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion.

Authors:  N Mitsiades; V Poulaki; G Mastorakos; S T Tseleni-Balafouta; V Kotoula; D A Koutras; M Tsokos
Journal:  J Clin Endocrinol Metab       Date:  1999-08       Impact factor: 5.958

5.  Fas ligand reduces viability in primary melanoma short-term cell cultures more than in metastatic melanoma short-term cell cultures.

Authors:  Günther F L Hofbauer; Naohito Hatta; Isabelle Daigle; Silvio Hemmi; Katharina Spanaus Schlapbach; Jörg Willers; Günter Burg; Hans-Uwe Simon; Reinhard Dummer
Journal:  Dermatology       Date:  2005       Impact factor: 5.366

6.  Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.

Authors:  M Santoro; F Carlomagno; I D Hay; M A Herrmann; M Grieco; R Melillo; M A Pierotti; I Bongarzone; G Della Porta; N Berger
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

7.  Increased salivary gland tissue expression of Fas, Fas ligand, cytotoxic T lymphocyte-associated antigen 4, and programmed cell death 1 in primary Sjögren's syndrome.

Authors:  Anne Isine Bolstad; Hans Geir Eiken; Benedikte Rosenlund; Marta E Alarcón-Riquelme; Roland Jonsson
Journal:  Arthritis Rheum       Date:  2003-01

8.  A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus.

Authors:  Satomi Kanemitsu; Kenji Ihara; Ahmed Saifddin; Takeshi Otsuka; Tsutomu Takeuchi; Jun Nagayama; Michihiko Kuwano; Toshiro Hara
Journal:  J Rheumatol       Date:  2002-06       Impact factor: 4.666

9.  Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia.

Authors:  Kathryn Sibley; Sara Rollinson; James M Allan; Alexandra G Smith; Graham R Law; Philippa L Roddam; Christine F Skibola; Martyn T Smith; Gareth J Morgan
Journal:  Cancer Res       Date:  2003-08-01       Impact factor: 12.701

10.  FAS (CD95) mutations are rare in gastric MALT lymphoma but occur more frequently in primary gastric diffuse large B-cell lymphoma.

Authors:  Sabine Wohlfart; David Sebinger; Petra Gruber; Judith Buch; Doris Polgar; Georg Krupitza; Margit Rosner; Markus Hengstschläger; Markus Raderer; Andreas Chott; Leonhard Müllauer
Journal:  Am J Pathol       Date:  2004-03       Impact factor: 4.307

View more
  5 in total

1.  Significant association among the Fas -670 A/G (rs1800682) polymorphism and esophageal cancer, hepatocellular carcinoma, and prostate cancer susceptibility: a meta-analysis.

Authors:  Tao Liu; Li Zuo; Lin Li; Lei Yin; Kai Liang; Hongyuan Yu; Hui Ren; Wen Zhou; Hongwei Jing; Yang Liu; Chuize Kong
Journal:  Tumour Biol       Date:  2014-08-02

2.  Fas/FasL gene polymorphism in patients with Hashimoto's thyroiditis in Turkish population.

Authors:  M Erdogan; M Kulaksizoglu; S Ganidagli; A Berdeli
Journal:  J Endocrinol Invest       Date:  2016-08-30       Impact factor: 4.256

3.  The FAS ligand promoter polymorphism, rs763110 (-844C>T), contributes to cancer susceptibility: evidence from 19 case-control studies.

Authors:  Zhizhong Zhang; Lixin Qiu; Meilin Wang; Na Tong; Jin Li; Zhengdong Zhang
Journal:  Eur J Hum Genet       Date:  2009-04-01       Impact factor: 4.246

4.  FASL rs763110 polymorphism contributes to cancer risk: an updated meta-analysis involving 43,295 subjects.

Authors:  Lei Xu; Xin Zhou; Feng Jiang; Man-Tang Qiu; Zhi Zhang; Rong Yin; Lin Xu
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

Review 5.  Association of the polymorphisms in the Fas/FasL promoter regions with cancer susceptibility: a systematic review and meta-analysis of 52 studies.

Authors:  Yeqiong Xu; Bangshun He; Rui Li; Yuqin Pan; Tianyi Gao; Qiwen Deng; Huiling Sun; Guoqi Song; Shukui Wang
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.